BlackRock Health Sciences Term Trust (NYSE:BMEZ) to Issue Dividend of $0.18

BlackRock Health Sciences Term Trust (NYSE:BMEZ) announced a dividend on Thursday, January 2nd,NASDAQ Dividends reports. Stockholders of record on Wednesday, January 15th will be given a dividend of 0.1782 per share on Friday, January 31st. The ex-dividend date of this dividend is Wednesday, January 15th.

BlackRock Health Sciences Term Trust has raised its dividend payment by an average of 20.7% annually over the last three years.

BlackRock Health Sciences Term Trust Price Performance

NYSE:BMEZ traded up $0.52 during trading hours on Friday, hitting $15.00. 722,833 shares of the company traded hands, compared to its average volume of 513,116. BlackRock Health Sciences Term Trust has a twelve month low of $14.27 and a twelve month high of $16.59. The firm has a 50-day moving average of $15.33 and a 200 day moving average of $15.56.

Insider Activity

In other news, major shareholder Saba Capital Management, L.P. bought 29,795 shares of BlackRock Health Sciences Term Trust stock in a transaction that occurred on Wednesday, October 16th. The stock was purchased at an average cost of $15.81 per share, with a total value of $471,058.95. Following the completion of the transaction, the insider now directly owns 20,750,913 shares in the company, valued at $328,071,934.53. This trade represents a 0.14 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

About BlackRock Health Sciences Term Trust

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.